SYN-004 is under clinical development by Synermore Biologics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SYN-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SYN-004 overview

SYN-004 is under development for the treatment of solid tumors including head and neck cancer squamous cell carcinoma, metastatic colorectal cancer and non-small cell lung cancer. The drug candidate is administered through intravenous route. The drug candidate is a recombinant chimeric monoclonal antibody which acts by targeting epidermal growth factor receptor (EGFR).

Synermore Biologics overview

Synermore Biologics (Synermore) is a biotechnology company that researches and develops biosimilar monoclonal antibodies. It develops its products in the therapeutic areas of oncology, immune disorders and infectious diseases. Synermore has developed technologies and platforms necessary for the development and production of therapeutic monoclonal antibodies including preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, and antibody drug formulation. The company also operates though its office located in Suzhou, China. Synermore is headquartered in Taipei City, Taiwan.

For a complete picture of SYN-004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.